Related Experiment Videos
Gene therapy in cystic fibrosis
1Powell Gene Therapy Center, University of Florida Genetics Institute, Gainesville, FL, USA. flotttr@peds.ufl.edu
Chest
|September 14, 2001
Summary
Neonatal gene therapy using cystic fibrosis transmembrane conductance regulator (CFTR) gene replacement shows promise for reducing cystic fibrosis (CF) complications. Adeno-associated virus (AAV) vectors and targeted spray delivery offer potential advantages over earlier methods.
Area of Science:
- Gene Therapy
- Pulmonary Medicine
- Molecular Biology
Background:
- Cystic fibrosis (CF) is a genetic disorder impacting multiple organs, primarily the lungs.
- Neonatal gene replacement therapy targeting the cystic fibrosis transmembrane conductance regulator (CFTR) gene offers theoretical benefits for reducing CF morbidity and mortality.
- Current research addresses challenges in vector choice, airway delivery, genetic translocation, and sufficient CFTR gene expression.
Purpose of the Study:
- To review the current landscape of gene therapy vectors for CFTR gene replacement.
- To evaluate the advantages and limitations of viral (adenovirus, adeno-associated virus) and non-viral (cationic liposomes) vectors.
- To assess different modes of pulmonary vector delivery, focusing on spray technology versus nebulization.
Main Methods:
- Review of existing literature on viral and non-viral gene therapy vectors for CFTR.
- Analysis of studies comparing aerosolized vector delivery methods (nebulization vs. spray technology).
- Examination of immune responses and gene expression levels associated with different vector types.
Main Results:
- Adenovirus (Ad) vectors show efficient gene transfer but can cause dose-limiting inflammatory effects and humoral immunity issues.
- Adeno-associated virus (AAV) vectors appear safe with good duration profiles, though assessing CFTR mRNA expression is challenging.
- Cationic liposomes are less efficient but do not elicit inflammatory or immunologic responses.
- Spray technology for aerosolized AAV vector delivery results in more localized deposition in central airways compared to nebulization, potentially reducing adverse effects.
Conclusions:
- Gene therapy holds promise for cystic fibrosis, with ongoing advancements in vector development and delivery systems.
- AAV vectors and targeted spray delivery represent promising strategies for improving the safety and efficacy of CFTR gene therapy.
- Further research is needed to overcome challenges related to immune responses and optimize gene expression for clinical application.